| 糖尿病性黄斑水肿患者行玻璃体内皮质类固醇植入后眼压的监测和管理——2022年欧洲专家共识解读 |
| |
| 引用本文： | 邵毅,王怡欣,漆怡晨. 糖尿病性黄斑水肿患者行玻璃体内皮质类固醇植入后眼压的监测和管理——2022年欧洲专家共识解读[J]. 眼科新进展, 2022, 0(5): 337-341. DOI: 10.13389/j.cnki.rao.2022.0068 |
| |
| 作者姓名： | 邵毅 王怡欣 漆怡晨 |
| |
| 作者单位： | 330006 江西省南昌市，南昌大学第一附属医院眼科（邵毅，漆怡晨）；CF244HQ 威尔士卡迪夫市，卡迪夫大学眼科学与视觉科学系（王怡欣） |
| |
| 摘 要： | 向玻璃体内植入皮质类固醇药物是治疗糖尿病性黄斑水肿的有效方法，但存在引起患者高眼压的副作用。为规范皮质类固醇植入物的临床使用，一些来自欧洲各地的眼科专家近期发布了关于“糖尿病性黄斑水肿患者行玻璃体内皮质类固醇植入后眼压的监测和管理”的共识，本文对该共识进行全面解读。
|
| 关 键 词： | 皮质类固醇植入物 眼压 玻璃体内植入 糖尿病性黄斑水肿 |
Monitoring and management of intraocular pressure after corticosteroid implantation in diabetic macular edema: interpretation of updated European experts consensus 2022 |
| |
| SHAO Yi1,WANG Yixin2,QI Yichen1. Monitoring and management of intraocular pressure after corticosteroid implantation in diabetic macular edema: interpretation of updated European experts consensus 2022[J]. Recent Advances in Ophthalmology, 2022, 0(5): 337-341. DOI: 10.13389/j.cnki.rao.2022.0068 |
| |
| Authors: | SHAO Yi1 WANG Yixin2 QI Yichen1 |
| |
| Affiliation: | 1.Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China2.School of Optometry and Vision Sciences,Cardiff University,Cardiff CF244HQ,Wales |
| |
| Abstract: | Intravitreal corticosteroid implantation is an effective therapy for treating diabetic macular edema, but it may cause side effects such as high intraocular pressure in patients. In order to standardize the clinical use of corticosteroid implants, some European ophthalmologists have recently released a consensus on monitoring and management of intraocular pressure after corticosteroid implantation in diabetic macular edema. The consensus is fully interpreted in this paper. |
| |
| Keywords: | corticosteroid implant intraocular pressure intravitreal implantation diabetic macular edema |
|
| 点击此处可从《眼科新进展》浏览原始摘要信息 |
|
点击此处可从《眼科新进展》下载免费的PDF全文 |
